Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis
International Archives of Allergy and Immunology · 2024
DOI: 10.1159/000542797 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Jinting Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Children's Medical Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, inining6969@163.com. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Biological Products, Biological Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Emerging evidence has underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic.
Methods
The databases of PubMed, Embase, Web of Science, and Cochrane Library were comprehensively searched in our study until May 29, 2024. Only randomized controlled trials were included to estimate the value of biologics on asthmatic children and adolescents. Data extraction and risk of bias assessment were independently performed by two researchers. Outcomes were analyzed by a fixed effects model, and the surface under the cumulative ranking (SUCRA) scores were calculated to determine the likelihood of each biologic being the most effective intervention.
Results
2,672 patients were included for comparing four different biologics (dupilumab, omalizumab, lebrikizumab, and mepolizumab) with a placebo. Dupilumab has been demonstrated to have the highest efficacy in reducing asthmatic exacerbations, improving lung function, and improving patients’ quality of life, with the SUCRA values of 0.956, 0.999, and 0.897, respectively. Omalizumab showed the best safety potential by reducing the risk of adverse and severe events, with the SUCRA values of 0.876 and 0.930.
Conclusions
In this NMA, focusing on biologics that target type 2 inflammation in childhood and adolescent asthma, four biologics demonstrated a favorable safety profile. Notably, dupilumab emerged as the most effective, while omalizumab was identified as the safest therapy. Further studies must be conducted in order to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Children's Medical Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, inining6969@163.com.
- Department of Pediatrics, Children's Medical Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Department of Allergy, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zitieren
APA
Lin, J., Yang, K., Zhou, Q., Ye, Q., Chen, Z., Zhang, P., Zhou, M., & Pan, L. (2024). Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis. International Archives of Allergy and Immunology. https://doi.org/10.1159/000542797
Vancouver
Lin J, Yang K, Zhou Q, Ye Q, Chen Z, Zhang P, et al. Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis. International Archives of Allergy and Immunology. 2024. doi:10.1159/000542797
BibTeX
@article{Lin2024,
author = {Lin, Jinting and Yang, Kexin and Zhou, Qilin and Ye, Qiqing and Chen, Zhuanggui and Zhang, Pingping and Zhou, Min and Pan, Li},
title = {Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis},
journal = {International Archives of Allergy and Immunology},
year = {2024},
doi = {10.1159/000542797}
}
EUVIMED